newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Reports Second Quarter Financial Results 2023

Provided R&D update on GPCR-targeted pipeline, including nomination of lead candidate for OXER1 antagonist programClosed June 30, 2023 with over CAD 19 million cash on hand, expecting to provide cash runway into